JAG1 and liver disorder: A second candidate genetic modifier, THROMBOSPONDIN2 (THBS2), was identified from a Genome Wide Association Study (GWAS) that stratified ALGS patients with pathogenic variants in JAG1 by whether they had mild or severe liver disease (Tsai et al., 2016).